Sepsis is a life-threatening syndrome of dysregulated host immune response to infection that currently lacks specific laboratory indicators for reliable differential diagnosis and outcome assessment. The study sought to characterize immune cell heterogeneity and identify surface molecules that could serve as sepsis-specific diagnostic and prognostic markers, with the goal of informing personalized therapeutic strategies.
The authors used combined transcriptomic and proteomic profiling to nominate immune cell–related molecules. These candidate markers were then assembled into a detection panel for cytometry by time-of-flight (CyTOF) analysis in order to resolve immune cell phenotypes at single-cell resolution. The abstract summarizes this multi-omics to CyTOF workflow but does not report detailed sample sizes, cohort characteristics, or full experimental parameters in the source text.
Using CyTOF, three distinct neutrophil subsets were identified in sepsis patients and characterized by surface marker patterns:
These subsets were reported to correlate with clinical measures of sepsis severity, disease progression, and patient prognosis, indicating functional heterogeneity among circulating neutrophils in sepsis.
The study reports dynamic changes in neutrophil surface marker expression over the course of acute sepsis. In the acute stage, the numbers of neutrophils positive for CD54 and CD62L increased. Their expression then declined as the disease progressed, but the kinetics differed by severity subgroup:
These temporal patterns suggest that early surface expression of CD54 and CD62L on neutrophils, and the rate of their decline, may reflect severity and trajectory of sepsis.
Beyond membrane expression on neutrophils, the study evaluated circulating forms of CD54:
Analysis of a proteomics dataset (PXD027485) showed elevated serum soluble CD54 (sCD54) in sepsis patients versus controls (p < 0.0001) with a reported area under the receiver operating characteristic curve (AUC) of 0.9627 in that dataset.
Independent targeted proteomic validation by parallel reaction monitoring (PRM) confirmed higher sCD54 in sepsis cohorts (p = 0.0242) with AUC = 0.9433.
In a rat sepsis model, plasma exosomal CD54 levels were increased (p = 0.0013), supporting the observation of CD54 elevation in a preclinical model.
These complementary lines of evidence—membrane expression on neutrophils, serum soluble CD54, and exosomal CD54 in an animal model—support CD54 as a candidate sepsis-specific biomarker.
The abstract provides specific statistical comparisons and diagnostic metrics for CD54:
No additional numerical details (for example, sensitivity, specificity, confidence intervals, or sample counts) are reported in the source abstract.
The authors conclude that three identified neutrophil subsets and CD54 represent sepsis-specific indicators with potential utility for differential diagnosis and outcome assessment. These markers may enable stratification of patients by immune phenotype and disease trajectory, thereby guiding more personalized therapeutic approaches in sepsis management. The combination of single-cell phenotyping (CyTOF) and proteomic validation (PRM, dataset analysis, and animal model) provides a translational pathway from discovery to candidate clinical biomarker.
The source text is an abstract and therefore omits many methodological and contextual details necessary for full clinical appraisal. Specifically, the abstract does not report cohort sizes, patient demographics, inclusion/exclusion criteria, full methods for CyTOF panel design and gating, or external clinical validation beyond the described datasets and PRM cohorts. The abstract also does not detail potential confounders, how severity groups were defined, or full performance metrics (sensitivity, specificity, confidence intervals). These gaps would need to be addressed by consulting the full article for confirmation before clinical implementation or guideline-level recommendations.